Healthcare costs have risen owing to highly priced pharmaceuticals, especially biologic drugs. Governments all over the world are emphasizing on the production of cost-effective drug synthesis. Estimates from Centers for Medicare and Medicaid Services state healthcare spending increased by 4.3% in the year 2016, amounting to over USD 3.3 trillion. These facts are indicative of the rising healthcare expenditure in the country and in the recent past, the government has been emphasizing on reducing healthcare expenditure. The implementation of Obamacare in the year 2010 has particularly been beneficial in accelerating market potential by reforming U.S. healthcare at large. Asian countries such as India, Japan, and China consist of large population bases and escalating healthcare costs are facilitating a gradual switch towards biosimilars. Various initiatives undertaken by national governments are expected to further expel market growth in the near future. Japan ranks second in the pharmaceutical market, following closely after the U.S. and various strategies undertaken by the government to evade the Asian economic crisis. Therefore, price regulations in Japan and price cuts formulated in India’s health budget have raised cost containment demands in healthcare industry at large. The current financial and economic crisis and the presence of a significant number of aging people are the key reasons to impose cost containment in healthcare systems. This brings to light the need for developing new, improved, and cost-effective methods for the synthesis of these drugs. Thus, the emphasis on bringing down the healthcare expenditure is expected to boost the market of biosimilars.

CHAPTER 01 Methodology and Scope

CHAPTER 02 Executive Summary

CHAPTER 04 Biosimilars Market: Product Analysis

CHAPTER 05 Biosimilars Market: Application Analysis

CHAPTER 06 Biosimilars Market: Regional Estimates & Trend Analysis, by Product, Application

CHAPTER 07 Competitive Landscape